Filtros de búsqueda

Lista de obras de

"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia

artículo científico publicado en 2010

"To switch or not to switch: that is the question"-more than 10% of ratio @ 3 months: how to treat chronic myeloid leukemia patients with this response?

artículo científico publicado en 2013

5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials

artículo científico publicado en 2012

AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation

artículo científico publicado en 2002

Absence of chromosome heterogeneity between classical Fanconi's anemia and the Estren-Dameshek type

Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease

artículo científico publicado en 2008

Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients

artículo científico publicado en 2011

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

artículo científico publicado en 2015

Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

artículo científico publicado en 2012

Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

artículo científico publicado en 2016

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms

artículo científico publicado en 2015

Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response

artículo científico publicado en 2012

Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib

artículo científico publicado en 2013

Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment

artículo científico publicado en 2014

Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?

artículo científico publicado en 2009

Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation

artículo científico publicado en 2013

Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization

artículo científico publicado en 2012

Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy

artículo científico

Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN.

artículo científico publicado en 2015

Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors

artículo científico publicado en 2017

Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development?

artículo científico publicado en 2005

Can we safely discontinue imatinib? Searching for new endpoints in CML: a standardized definition of "cure".

artículo científico publicado en 2012

Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience

artículo científico publicado en 2007

Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC).

artículo científico publicado en 2015

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion

artículo científico publicado en 2010

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

artículo científico publicado en 2011

Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase

artículo científico publicado en 2015

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

artículo científico

Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?

artículo científico publicado en 2012

Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation.

artículo científico publicado en 2005

Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution

artículo científico publicado en 2004

Clofarabine-Based Regimen as Useful Bridge Therapy for Allogeneic Transplantation in Myeloid Blast Crisis of Philadelphia-Positive Chronic Myeloid Leukemia Resistant to Imatinib and Dasatinib ⬇️

artículo científico publicado el 11 de octubre de 2010

Cocaine abuse may influence the response to imatinib in CML patients

artículo científico publicado en 2007

Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.

artículo científico publicado en 2009

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment

artículo científico publicado en 2006

Comparison of JAK2(V617F) -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology

artículo científico publicado en 2017

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

artículo científico publicado en 2009

Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia

artículo científico publicado en 2012

Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy

artículo científico publicado en 2010

Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront.

artículo científico publicado en 2015

Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.

artículo científico

Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib

artículo científico

Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen

artículo científico publicado en 2002

Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose

artículo científico publicado en 2010

Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life

artículo científico publicado en 2010

Dasatinib first-line: Multicentric Italian experience outside clinical trials

artículo científico publicado en 2015

Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations

artículo científico publicado en 2009

Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance

artículo científico publicado en 2009

Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results

artículo científico publicado en 2009

Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.

artículo científico publicado en 2012

Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response

artículo científico publicado en 2010

Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis

artículo científico publicado en 2010

Diabetes insipidus as first manifestation of acute myeloid leukaemia with EVI-1-positive, 3q21q26 syndrome and T cell-line antigen expression: what is the EVI-1 gene role?

artículo científico publicado en 2002

Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia

artículo científico publicado en 2008

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

artículo científico publicado en 2018

Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response

artículo científico publicado en 2015

Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia

artículo científico

Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease.

artículo científico publicado en 2002

Early and late complications related to central venous catheters in hematological malignancies: a retrospective analysis of 1102 patients

artículo científico

Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.

artículo científico publicado en 2007

Early molecular response in chronic myeloid leukemia and halving time: Latest evidences

artículo científico publicado en 2016

Efficacy and safety of deferasirox in myelodysplastic syndromes

artículo científico publicado en 2013

Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase

artículo científico publicado en 2016

Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment

artículo científico publicado en 2005

Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes

artículo científico publicado en 2010

Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.

artículo científico publicado en 2010

Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes

artículo científico publicado en 2011

Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib

artículo científico publicado en 2004

Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes

artículo científico publicado en 2012

Firstline treatment for chronic phase chronic myeloid leukemia patients should be based on a holistic approach

artículo científico publicado en 2014

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

artículo científico publicado en 2016

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

article by Gabriele Gugliotta et al published 26 May 2011 in Blood

Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome

artículo científico publicado en 2013

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

artículo científico publicado en 2011

Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy

artículo científico publicado en 2014

How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety

artículo científico publicado en 2016

How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages

artículo científico

How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review

artículo científico publicado en 2014

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

artículo científico publicado en 2016

Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up

artículo científico publicado en 2010

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

artículo científico publicado en 2013

Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?

artículo científico publicado en 2010

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

artículo científico publicado en 2012

Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia

artículo científico publicado en 2015

Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?

artículo científico publicado en 2015

Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib

artículo científico publicado en 2014

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

artículo científico publicado en 2012

Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.

artículo científico publicado en 2011

Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.

artículo científico publicado en 2011

Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose

artículo científico publicado en 2008

Isolated myeloid sarcoma without bone marrow involvement

artículo científico publicado en 2012

Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy

artículo científico publicado en 2013

Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia

artículo científico publicado en 2008

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

artículo científico publicado en 2015

Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase

artículo científico publicado en 2011

MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine

artículo científico publicado en 2012

Management of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center

artículo científico publicado en 2011

Management options for refractory chronic myeloid leukemia: considerations for the elderly

artículo científico publicado en 2013

Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment

artículo científico publicado en 2009

Myelodysplastic syndromes in patients under 50 years old: a single institution experience.

artículo científico publicado en 2005

NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia ⬇️

artículo científico publicado el 1 de noviembre de 2010

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

artículo científico publicado en 2007

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

artículo científico

Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy

artículo científico publicado en 2007

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

artículo científico publicado en 2009

Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences.

artículo científico publicado en 2011

Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.

artículo científico publicado en 2009

Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index

artículo científico publicado en 2012

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia

artículo científico publicado en 2010

Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors

artículo científico publicado en 2013

Ocular side effects in chronic myeloid leukemia patients treated with imatinib

artículo científico publicado en 2007

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

artículo científico publicado en 2012

Pain and anxiety associated with bone marrow aspiration and biopsy: a prospective study on 152 Italian patients with hematological malignancies ⬇️

artículo científico publicado el 2 de febrero de 2011

Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis

artículo científico publicado en 2016

Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib

artículo científico publicado en 2005

Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development

artículo científico publicado en 2010

Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience

artículo científico publicado en 2011

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib

artículo científico publicado en 2017

Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience

artículo científico publicado en 2012

Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?

artículo científico publicado en 2012

Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline

artículo científico publicado en 2016

Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians

artículo científico publicado en 2011

Recurrent Sweet's syndrome in acute myeloid leukemia successfully treated with amphotericin B.

artículo científico publicado en 2004

Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance

artículo científico publicado en 2010

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib ⬇️

artículo científico publicado el 1 de octubre de 2008

Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients

artículo científico publicado en 2010

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study

artículo científico publicado en 2007

Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem

scientific article published on March 2009

Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia.

artículo científico publicado en 2004

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

artículo científico publicado en 2009

Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine

artículo científico publicado en 2012

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

artículo científico publicado en 2016

Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia

artículo científico publicado en 2017

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

artículo científico publicado en 2016

Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months

artículo científico publicado en 2010

Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs

artículo científico

Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.

artículo científico publicado en 2009

Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?

artículo científico publicado en 2009

Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients

artículo científico publicado en 2016

Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challenges

artículo científico

Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide ⬇️

artículo científico publicado el 12 de enero de 2011

Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms

article

Systematic review of dasatinib in chronic myeloid leukemia

artículo científico publicado en 2013

The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose

artículo científico publicado en 2011

The degree of anemia has an impact on survival in myelodysplastic syndrome patients classified with WPSS.

artículo científico publicado en 2011

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

artículo científico publicado en 2009

The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism

artículo científico publicado en 2009

The pros and cons of new prognostic eutos score for chronic myeloid leukemia patients

artículo científico publicado en 2013

The role of comorbidities in chronic myeloid leukemia

artículo científico publicado en 2013

The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era ⬇️

artículo científico publicado el 4 de agosto de 2010

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response

artículo científico publicado en 2009

Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.

artículo científico publicado en 2011

Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data

artículo científico publicado en 2012

Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient

artículo científico publicado en 2009

Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes

artículo científico publicado en 2005

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda